ArticleClinical ophthalmology (Auckland, N.Z.)2026
Management of Post-Operative Inflammation After Cataract Surgery with Intracanalicular Dexamethasone Implant and Topical Ketorolac.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the safety of an intracanalicular dexamethasone ophthalmic insert (IDOI) and topical Ketorolac tromethamine 0.5% (ketorolac) versus ketorolac and topical prednisolone acetate 1% (PA) over the first month after cataract surgery (POM1). Patients and Methods: Retrospective study of uncomplicated cataract surgeries between June 2020 and March 2023 at the University of Michigan. Patients received either IDOI and ketorolac or PA and ketorolac (control) during POM1. Outcomes included breakthrough inflammation necessitating additional anti-inflammatory drops, cystoid macular edema, and increased intraocular pressure at POM1. Results: 100 eyes of 78 patients were included in the IDOI/ketorolac group, and 102 eyes of 83 individuals in the control group. Demographics, ocular comorbidities, and baseline IOP were comparable between groups. There were no differences between groups in the distribution of race (p = 0.137), the preoperative presence of epiretinal membrane (43.5% vs 57.83%; p = 0.88), or history of diabetic retinopathy (19.23% vs 15.6%; p = 0.59) in the surgical eyes. There were no differences in the rates of postoperative rebound inflammation in the IDOI/ketorolac compared to the PA/ketorolac group (2.0% vs 2.0%; p = 1.00) or in the development of cystoid macular edema (2.0% vs 2.9%; p = 1.00). There were no cases of increased IOP > 10 mmHg at POM1 compared with baseline in either group. Conclusion: There was no difference in the rate of rebound inflammation or CME in the IDOI/ketorolac regimen compared to the PA/ketorolac regimen. IDOI can be a safe and effective dropless alternative to PA/ketorolac therapy after cataract surgery in patients susceptible to inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.